Patent classifications
C07F9/5435
Mitochondria-Targeted Atovaqone: A More Potent and More Effective Antitumor, Antimicrobial, and Antimalarial Drug
The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.
Azithromycin derivatives containing a phosphonium ion as anticancer agents
This invention relates to compounds that are useful as cancer therapies. The compounds comprise azithromycin derivatives having a phosphonium cation tethered to the azithromycin macrocycle. The invention also relates to methods of using said compounds and the pharmaceutical formulations comprising said compounds.
NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF
Disclosed herein are compounds related to nicotinate and nicotinamide riboside and methods of making and using said compounds. Also disclosed herein are methods of making nicotinic acid mononucleoside (NAMN).
Phosphonium-ion tethered tetracycline drugs for treatment of cancer
This invention relates to compounds that are useful as cancer therapies. The compounds comprise derivatives of tetracycline antibiotics, e.g. doxycycline, having a phosphonium cation tethered to the tetracycline tetracycle. The invention also relates to methods of using said compounds and to pharmaceutical formulations comprising said compounds.
Zwitterion-ruthenium complex for catalytic aerobic oxidation reactions
Zwitterion ligand metal complexes and methods of aerobic oxidation using a zwitterion ligand metal complex are provided. The zwitterion ligand metal complexes can include a transition metal salt and a zwitterion ligand, which can comprise a non-conjugated amide anion-phosphonium cation, an amide anion-ammonium cation, or an iminium cation. The methods of aerobic oxidation can include combining the zwitterion ligand metal complex with an oxidizable compound and molecular oxygen to allow the isolation of an oxidized compound from the oxidizable compound.
AZITHROMYCIN DERIVATIVES CONTAINING A PHOSPHONIUM ION AS ANTICANCER AGENTS
This invention relates to compounds that are useful as cancer therapies. The compounds comprise azithromycin derivatives having a phosphonium cation tethered to the azithromycin macrocycle. The invention also relates to methods of using said compounds and the pharmaceutical formulations comprising said compounds.
ZWITTERION-RUTHENIUM COMPLEX FOR CATALYTIC AEROBIC OXIDATION REACTIONS
Zwitterion ligand metal complexes and methods of aerobic oxidation using a zwitterion ligand metal complex are provided. The zwitterion ligand metal complexes can include a transition metal salt and a zwitterion ligand, which can comprise a non-conjugated amide anion-phosphonium cation, an amide anion-ammonium cation, or an iminium cation. The methods of aerobic oxidation can include combining the zwitterion ligand metal complex with an oxidizable compound and molecular oxygen to allow the isolation of an oxidized compound from the oxidizable compound.
PHOSPHONIUM-ION TETHERED TETRACYCLINE DRUGS FOR TREATMENT OF CANCER
This invention relates to compounds that are useful as cancer therapies. The compounds comprise derivatives of tetracycline antibiotics, e.g. doxycycline, having a phosphonium cation tethered to the tetracycline tetracycle. The invention also relates to methods of using said compounds and to pharmaceutical formulations comprising said compounds.
Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
Provided are stable liquid and solid formulations of oxidized and reduced mitochondria-targeted antioxidants, and methods of their preparation and use.
PHOSPHORUS-CONTAINING PASSIVATOR, PEROVSKITE SOLAR CELL, PHOTOVOLTAIC MODULE, PHOTOVOLTAIC SYSTEM, AND ELECTRIC APPARATUS
A phosphorus-containing passivator, a perovskite solar cell, a photovoltaic module, a photovoltaic system, and an electric apparatus are provided. The phosphorus-containing passivator includes an ionic compound, the ionic compound includes a cationic group, and the cationic group has a structure represented by formula (I): A-L-B (I); where A represents an organophosphorus group with lone pair electrons, B represents a positively charged organophosphorus salt group, and L represents a linking group between the organophosphorus group and the organophosphorus salt group. The lone pair electrons of the organophosphorus group can form strong PPb coordination bonds with under-coordinated lead ions in the bulk phase and/or at the upper and lower interfaces of a perovskite light-absorbing layer, passivating low-coordinated lead ion defects; the organophosphorus salt group can form low-dimensional perovskite at the upper and lower interfaces of a perovskite layer, passivating the interfaces of the perovskite layer and suppressing ion migration.